2009China Venture Capital and Private Equity Investment Mid-Term Forum was held in Beijing on July9-10. JulyOn October 10, at the forum, Zero2IPO Group announced the fourth “Zero2IPO – China’s most valuable investment enterprise 0px;border: 0px;font: inherit;vertical-align: baseline”>Venture 50) list. Shenzhen Beike Biotechnology Co., Ltd. ranked 12.
Beike Biotechnology is a biotech enterprise in China specializing in basic stem cell research, clinical application research and stem cell technology services. In terms of stem cell clinical application research and technical services, Beike Biotech has always kept pace with international development. Beike Biotech has a strong sense of mission for the development of China’s biomedical technology and aims to enable China’s biomedical industry to occupy a place in international competition through continuous and in-depth research on stem cell basic research and clinical application technology.
This year’s50 companies cover all five major industries, and the biotechnology to which Beike Biotechnology belongs/There are 8 companies on the list in the health category, among which Beike Biotechnology ranks among the top three. Most of the companies on the list still have the ability to grow against the trend in 2008 when the economic situation suddenly turned cold and have recently completed a new round of financing. This vitality has attracted great attention from venture capital institutions.
The commonality of the companies on the list that most attract investors is their high growth. As a start-up company established just four years ago, Beike Biotech’s strong vitality and growth not only demonstrate the correctness and scientificity of the company’s planning blueprint, but also demonstrate the harmonious scene of the company’s unity and collaboration for development. At the same time, Beike Biotech’s innovative business model is also a major attraction for investors.
This year’s “Qingdao–China’s Most Investment Valuable Enterprise50Top” selection activity is organized and invited by Zero2IPO Group69 top venture capitalists jointly participated in the selection, and conducted in-depth consideration of the management team and ownership structure, company business, business model and competitiveness, industry and market, financial status and forecast, operating risks and countermeasures of the participating companies, and finally selected from thousands of nominations in major industries across the country50 companies with the most investment value in the eyes of venture capitalists. At present, this selection activity has become China’s most authoritative venture capital investor’s selection of enterprises, and is a benchmark for companies with the most growth potential of the year.
For details, please log in to the links on Sina and Phoenix.com for the selection activities:
http://tech.sina.com.cn/chuangye/2009-07-10/17363253996.shtml
http://finance.ifeng.com/stock/zqyw/20090715/937517.shtml